$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost Debt Structure and Includes Retiring Prior Term Loan Company Reiterates 2020 Galafold Revenue of $250-$260M and 2020 Operating Expense Guidance CRANBURY, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, develop
July 17, 2020
· 5 min read